What is Penumbra, Inc. (PEN) stock price today?

Penumbra, Inc. (PEN) is currently trading at $319.40, up 0.59% today.

What is PEN P/E ratio?

Penumbra, Inc.'s P/E ratio is 77.64. This is above the market average, reflecting high growth expectations.

What is PEN return on equity (ROE)?

Penumbra, Inc.'s return on equity (ROE) is 11.09%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Penumbra, Inc.'s market cap?

Penumbra, Inc. has a market capitalization of $12.58B.

NYSE · Medical - Devices

Penumbra, Inc. (PEN) Stock

$319.40 +0.59% NYSE: PEN Healthcare

Valuation

Metric	Value
Price	$319.40
Market Cap	$12.58B
P/E Ratio	77.64
P/B Ratio	8.16
P/S Ratio	8.31
EPS (TTM)	$4.52
52-Week High	$362.41
52-Week Low	$221.26
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	11.09%
ROA	8.13%
ROCE	10.76%
Gross Margin	13.53%
Operating Margin	13.46%
Net Margin	10.67%
Debt/Equity	0.14
Current Ratio	6.65

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$748.0M	$847.0M	$1.1B	$1.2B	$1.4B
Operating Profit	$-8.0M	$6.0M	$74.0M	$86.0M	$189.0M
Net Profit	$5.0M	$-2.0M	$91.0M	$14.0M	$178.0M
EPS	$0.14	$-0.05	$2.32	$0.36	$4.52
Op Margin	-1.0%	0.7%	7.0%	7.2%	13.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.2B	$1.4B	$1.6B	$1.5B	$1.8B
Total Liabilities	$290.0M	$372.0M	$377.0M	$382.0M	$399.0M
Cash	$59.0M	$70.0M	$167.0M	$324.0M	$187.0M
Borrowings	$174.0M	$236.0M	$234.0M	$223.0M	$220.0M

Latest News

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire · Jul 22, 2026 PEN: Raising target price to $349.00 Argus Research · Jul 22, 2026 3 Medical Device Stocks Giving Investors a Different Healthcare Play MarketBeat · Jul 20, 2026 IQV vs. PEN: Which Stock Is the Better Value Option? Zacks · Jul 14, 2026 First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke PR Newswire · Jul 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$10.0M	$-56.0M	$97.0M	$168.0M	$239.0M
Investing Cash Flow	$-43.0M	$35.0M	$-31.0M	$56.0M	$-468.0M
Financing Cash Flow	$-16.0M	$-8.0M	$-2.0M	$-102.0M	$-3.0M
Net Cash Flow	$-10.0M	$10.0M	$98.0M	$157.0M	$-138.0M
Free Cash Flow	$-12.0M	$-75.0M	$82.0M	$147.0M	$175.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	11.44
EV / EBITDA	56.31
FCF Yield	1.73%
Quick Ratio	3.86
Interest Coverage	144.22
Return 1Y	22.19%
Return 3Y	37.14%
Return 5Y	21.20%

Ownership

Insiders Held2.90%

Institutions Held87.07%

Institutions Float Held89.67%

Institutional Holder	Shares	Report Date
Blackrock Inc.	4,330,456	2026-03-31
Vanguard Capital Management LLC	1,694,488	2026-03-31
Vanguard Portfolio Management LLC	1,654,477	2026-03-31
HBK Investments L P	1,634,261	2026-03-31
State Street Corporation	1,185,811	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABTAbbott Laboratories	$99.60	+1.13%	32.57	$172.35B	2.49%
ANGOAngioDynamics, Inc.	$11.52	+2.58%	-17.17	$476.15M	0.00%
BSXBoston Scientific Corporation	$42.73	+1.64%	17.71	$63.51B	0.00%
EWEdwards Lifesciences Corporation	$85.21	+1.15%	49.59	$49.06B	0.00%
ISRGIntuitive Surgical, Inc.	$423.96	+2.06%	45.78	$149.78B	0.00%

About Penumbra, Inc.

Penumbra, Inc. is led by CEO Adam Elsesser, employs 4,700 people, headquartered in Alameda, US, publicly traded since 2015.

Penumbra, Inc. (PEN) stock trades at $319.40 with a market capitalization of $12.58B. The stock is valued at a price-to-earnings (P/E) ratio of 77.64, price-to-book of 8.16, price-to-sales of 8.31. Over the past 52 weeks the stock has ranged between $221.26 and $362.41, and currently trades 11.9% below its 52-week high.

On profitability, Penumbra, Inc. generates a return on equity (ROE) of 11.09%, return on capital employed of 10.76%, an operating margin of 13.46%, a net profit margin of 10.67%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks NYSE High ROE Stocks All stock screens

Run Stock Screener Investing Guides